Henrik Schmidt

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

Caroline Robert, Georgina V. Long, Benjamin Brady et al. · New England Journal of Medicine · 2014 · 5.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob et al. · New England Journal of Medicine · 2016 · 1.3K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob et al. · The Lancet Oncology · 2015 · 1.3K citations

Medicine, Oncology, Immunotherapy +15

An immune-active tumor microenvironment favors clinical response to ipilimumab

Rui‐Ru Ji, Scott D. Chasalow, Lisu Wang et al. · Cancer Immunology Immunotherapy · 2011 · 777 citations · Full text

Medicine, Immunology, Oncology +10

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Omid Hamid, Henrik Schmidt, Aviram Nissan et al. · Journal of Translational Medicine · 2011 · 531 citations · Full text

Medicine, Immunology, Oncology +17